Gamida Cell has raised new funding from a consortium including Novartis, a shareholder since 2014 when it invested $35m in the cellular therapy developer.

Israel-based cellular treatment and immunotherapy developer Gamida Cell secured $40m in funding on Monday from investors including pharmaceutical firm Novartis.

The round was led by investment firm Shavit Capital and included VMS Investment Group, Israel Biotech Fund, Clal Biotechnology Industries (CBI) and Israel Healthcare Ventures.

Gamida Cell is working on therapies for cancer, genetic haematological and metabolic diseases, and refractory autoimmune diseases. The company’s lead product, NiCord, is expected to facilitate bone marrow transplantation.

The funding will go towards the…